This early phase I trial studies the biological activity of OMO-103 in patients with pancreatic ductal adenocarcinoma that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). OMO-103 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This trial may help researchers determine how exposure to OMO-103 changes pancreatic tumor cells.
Must provide written informed consent before any study-specific procedures or interventions are performed
Must be ≥ 18 years old at the time of informed consent
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
Clinically-confirmed diagnosis of locally-advanced or metastatic adenocarcinoma of the pancreas
Concomitant use of other anti-cancer therapy otherwise not permitted in this protocol, including: chemotherapy, immunotherapy, hormonal therapy (hormone replacement therapy is acceptable), radiotherapy (except for palliative), biological therapy, or other novel agent
Prior anti-cancer therapy within 2 weeks prior to study enrollment
Prior treatment with a MYC inhibitor
Known severe hypersensitivity to OMO-103 or to any excipient of these medicinal products, or history of allergic reactions attributed to compounds of similar chemical or biologic composition
OHSU Knight Cancer Institute
Lead sponsor
Oregon Health and Science University
Collaborator
Brendon-Colson Center
Collaborator
Peptomyc S.L.
Collaborator